Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Curevac Netherlands B V currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This workload is distributed across a distinct examiner and a distinct art unit. The narrow scope of active matters indicates a focused prosecution phase for the company's current intellectual property. This concentration allows for a dedicated strategy that addresses the specific technical challenges of the biotechnology sector. The administrative burden is low, with a distinct examiner to manage.
VAN DRUFF, SYDNEY is the busiest examiner for this portfolio, overseeing 1 busiest examiner pending office action. This examiner handles the entirety of the company's active examiner-facing workload. Practitioners should prepare for interactions centered on this specific examiner's historical patterns within the Biotechnology & Pharmaceuticals field. The presence of a distinct art unit ensures that the prosecution strategy remains concentrated on a singular point of contact. Understanding this examiner's specific requirements will be key to resolving the pending office action efficiently.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAN DRUFF, SYDNEY | 1 | 55.0% | +31.7% |
| BAUSCH, SARAE L | 1 | 29.8% | +44.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17261997 | METHOD OF PREPARING SUBJECT-SPECIFIC IMMUNOGENIC COMPOSITIONS BASED ON A NEO OPEN-READING-FRAME PEPTIDE DATABASE | BAUSCH, SARAE L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17263258 | CANCER VACCINES FOR UTERINE CANCER | VAN DRUFF, SYDNEY | 19d |
| 17261997 | METHOD OF PREPARING SUBJECT-SPECIFIC IMMUNOGENIC COMPOSITIONS BASED ON A NEO OPEN-READING-FRAME PEPTIDE DATABASE | BAUSCH, SARAE L | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17263258 | CANCER VACCINES FOR UTERINE CANCER | VAN DRUFF, SYDNEY | 1643 | §103 | Final Rejection | 19d | Pending | Jan 26, 2021 |
| 17261997 | METHOD OF PREPARING SUBJECT-SPECIFIC IMMUNOGENIC COMPOSITIONS BASED ON A NEO OPEN-READING-FRAME PEPTIDE DATABASE | BAUSCH, SARAE L | 1699 | §101§112 | Non-Final OA | — | Pending | Jan 21, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial